- One time treatment may address underlying cause of the disease
- Works by inserting a functional human beta-globin gene into a patient’s own hematopoietic stem cells
- ... read more
Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL) announced on 6/14/2018 that it has initiated dosing in its phase 1 clinical trial of TTI-622 (SIRPaFc-IgG4), a checkpoint inhibitor of the... read more
Pharnext SA (... read more
Verseon will be starting a first-in-human phase I trial in Australia for its lead-PROAC (PRecision Oral AntiCoagulant) VE-1902, which has successfully completed regulatory toxicology studies and... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,